Abstract 286MO
Background
Cervical cancer is the second most common cancer in women in India. Recurrent / metastatic (R/M) cervical cancer carries a poor prognosis with median overall survival of 11 months with chemotherapy alone. Checkpoint inhibitors added to chemotherapy have improved survival. However, the current approved dose is accessible to only 1-3% of patients in low- and middle-income countries because of their cost. Nivolumab does not have a dose-response relationship; therefore, a low dose regimen may be a viable option to reduce financial burden and improve access.
Methods
This is a retrospective study from a single tertiary centre in India from 1/3/2020 to 30/6/2023. Patients with R/M cervical cancer who received low dose Nivolumab as they could not afford to pay for standard Nivolumab dose were analyzed. Response rates and Progression free survival (PFS) were measured.
Results
A total of 20 patients who received low dose Nivolumab were identified during the study period whose mean age was 54.3 years. 75% had ECOG of Patient and tumor characteristics
| Characteristic | nivolumab | |
| N | % | |
| Age (years) | ||
| 40-49 | 8 | 40 |
| 50-59 | 6 | 30 |
| 60-69 | 5 | 25 |
| 70-79 | 1 | 5 |
| Performance status | ||
| 0,1 | 15 | 75 |
| >/= 2 | 5 | 25 |
| Histology | ||
| Squamous | 14 | 70 |
| Non- squamous | 6 | 30 |
| Prior surgery | ||
| Yes | 17 | 85 |
| No | 3 | 15 |
| Prior RT | ||
| Yes | 17 | 85 |
| No | 3 | 15 |
| Prior chemotherapy | ||
| None | 6 | 30 |
| I line | 11 | 55 |
| II lines | 3 | 15 |
| Backbone chemotherapy with Nivolumab | ||
| Platinum based | 11 | 55 |
| None | 5 | 25 |
| Others | 4 | 2 |
The average number of doses received were 4.75 and the mean dose received was 0.84mg/kg. Overall responses were seen in 10 patients (50%) out of which 5 (50%) had stable disease and 5(50%) had a complete response. Median progression free survival was 7.97 months. Treatment related adverse events (TRAE) were seen in 8 patients (40%), out of which most of them are grade 1 and 2. 3 (15%) patients had grade 3 TRAE. No grade 4 and 5 adverse events were recorded.
Conclusions
In patients with R/M cervical cancer, Low dose Nivolumab is effective with manageable toxicity. It can help reduce financial toxicity and make it accessible to more patients especially in low- and middle-income countries where the burden of this disease is higher.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. Devabhaktuni.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
285O - Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study
Presenter: Svetlana Khokhlova
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
287MO - Real-world experience with maintenance PARP inhibitor plus minus bevacizumab in newly diagnosed advanced ovarian cancer with germline BRCA mutations or homologous recombination deficiency (HRD) positive
Presenter: Somnath Roy
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 285O, 286MO and 287MO
Presenter: Smruti Koppikar
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Webcast
288MO - InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
289MO - Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts): Results from a multicenter, single-arm phase II study
Presenter: Xiaotian Han
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
290MO - Efficacy and safety of topical sintilimab administration in conjunction with CRT and Californium-252 neutron brachytherapy in first-line advanced gynecological squamous cell carcinoma patients
Presenter: Xiaoling Li
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 288MO, 289MO and 290MO
Presenter: Alexandra Leary
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Webcast
LBA8 - Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
Presenter: Natalie Ngoi
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast